

In The Claims:

1-43. (Cancelled)

44. (New) An isolated frameshift polypeptide selected from the group consisting of: TAF1b (-1) ORF, SEQ ID NO: 20; TAF1b (+1) ORF, SEQ ID NO: 21; TAF1b (-2) ORF, SEQ ID NO: 120; HT001 (-1) ORF, SEQ ID NO: 2; HT001 (+1) ORF, SEQ ID NO: 3; and HT001 (-2) ORF, SEQ ID NO: 118.

45. (New) A fragment peptide comprising a fragment of the frameshift polypeptide according to Claim 44, wherein said fragment peptide comprises at least 3 amino acids of a mutated part of the frameshift polypeptide and has a length of at least 15 amino acids.

46. (New) The fragment peptide according to Claim 45, wherein said fragment peptide has an immunogenic portion with a length of about 10-20 amino acids.

47. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has SEQ ID NO: 20 and the three amino acids are TIL.

48. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has SEQ ID NO: 21 and the three amino acids are KQY.

49. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has SEQ ID NO: 2 and the three amino acids are GRR.

50. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has SEQ ID NO: 3 and the three amino acids are KAE.

51. (New) A pharmaceutical composition comprising the frameshift polypeptide according to Claim 44 and a physiologically acceptable carrier.

52. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 45 and a physiologically acceptable carrier.

53. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 47 and a physiologically acceptable carrier.

54. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 48 and a physiologically acceptable carrier.
55. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 49 and a physiologically acceptable carrier.
56. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 50 and a physiologically acceptable carrier.
57. (New) A diagnostic kit comprising the frameshift polypeptide according to Claim 44 as a reagent for detecting antibodies or cells specifically recognizing said frameshift polypeptide, and additional reagents and buffers for carrying out the detection reactions.
58. (New) A diagnostic kit comprising the fragment peptide according to Claim 45 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
59. (New) A diagnostic kit comprising the fragment peptide according to Claim 47 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
60. (New) A diagnostic kit comprising the fragment peptide according to Claim 48 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
61. (New) A diagnostic kit comprising the fragment peptide according to Claim 49 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
62. (New) A diagnostic kit comprising the fragment peptide according to Claim 50 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.
63. (New) A pharmaceutical composition comprising a physiologically acceptable carrier and a set of at least three frameshift polypeptides A, B, and C, wherein A is selected from the group consisting of TAF1b (-1) ORF, SEQ ID NO: 20; TAF1b (+1) ORF, SEQ ID NO: 21; and TAF1b (-2) ORF, SEQ ID NO: 120 ; B is selected from the group consisting of HT001 (-1) ORF, SEQ ID

NO: 2; HT001 (+1) ORF, SEQ ID NO: 3; and HT001 (-2) ORF, SEQ ID NO: 118; and C is selected from the group consisting of TGFbRII (-1) ORF, SEQ ID NO: 11; TGFbRII (+1) ORF, SEQ ID NO: 12; and TGFbRII (-2) SEQ ID NO: 119.

64. (New) A pharmaceutical composition comprising a physiologically acceptable carrier and a set of at least three fragment peptides each being a fragment of the frameshift polypeptide A, B, or C according to Claim 63, wherein each fragment peptide comprises at least 3 amino acids of a mutated part of the corresponding frameshift polypeptide has a length of at least 15 amino acids.

65. (New) The pharmaceutical composition according to Claim 64, wherein each fragment peptide has an immunogenic portion with a length of about 10-20 amino acids.

66. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide A has SEQ ID NO: 20 and the three amino acids are TIL.

67. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide A has SEQ ID NO: 21 and the three amino acids are KQY.

68. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide B has SEQ ID NO: 2 and the three amino acids are GRR.

69. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide B has SEQ ID NO: 3 and the three amino acids are KAE.

70. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide C has SEQ ID NO: 11 and the three amino acids are RLS.

71. (New) The pharmaceutical composition according to Claim 64, wherein the frameshift polypeptide C has SEQ ID NO: 12 and the three amino acids are KAW.

72. (New) A diagnostic kit comprising a set of at least three frameshift polypeptides A, B, and C as reagents for detecting antibodies or cells specifically recognizing said frameshift polypeptide, and additional reagents and buffers for carrying out the detection reactions, wherein A is selected from the group consisting of TAF1b (-1) ORF, SEQ ID NO: 20; TAF1b (+1) ORF, SEQ ID NO: 21; and TAF1b (-2) ORF, SEQ ID NO: 119; B is selected from the group consisting of HT001 (-1) ORF, SEQ ID NO: 2; HT001 (+1) ORF, SEQ ID NO: 3; and HT001 (-2) ORF, SEQ ID NO: 118;

and C is selected from the group consisting of TGFbRII (-1) ORF, SEQ ID NO: 11; TGFbRII (+1) ORF, SEQ ID NO: 12; and TGFbRII (-2), SEQ ID NO: 120.

73. (New) A diagnostic kit comprising (i) a set of at least three fragment peptides each being a fragment of the frameshift polypeptide A, B, or C according to Claim 70, as reagents for detecting antibodies or cells specifically recognizing said fragment peptide, and (ii) additional reagents and buffers for carrying out the detection reactions, wherein each fragment peptide comprises at least 3 amino acids of a mutated part of the corresponding frameshift polypeptide has a length of at least 15 amino acids.

74. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide A has SEQ ID NO: 20 and the three amino acids are TIL.

75. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide A has SEQ ID NO: 21 and the three amino acids are KQY.

76. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide B has SEQ ID NO: 2 and the three amino acids are GRR.

77. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide B has SEQ ID NO: 3 and the three amino acids are KAE.

78. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide C has SEQ ID NO: 11 and the three amino acids are RLS.

79. (New) The diagnostic kit according to Claim 73, wherein the frameshift polypeptide C has SEQ ID NO: 12 and the three amino acids are KAW.